SRX 0.00% 17.5¢ sierra rutile holdings limited

SIR 2017 - March 4-9th

  1. 8,917 Posts.
    lightbulb Created with Sketch. 32
    Should be an interesting meeting.

    Below is one of the sessions, and detailed the first sub session. Some well known co-authors on this paper.
    A fair few others of interest, hopefully.

    http://sirmeeting.org/index.cfm?do=ev.viewEv&ev=3309
    Using data from the SIRFLOX study to evaluate depth of response within a volumetric model in patients with metastatic colorectal cancer

    3:00 PM - 3:09 PM
    Final ID

    371

    View Abstract 371

    Co-Author(s)

    Michael Findlay, MD, Cancer Trials New Zealand  - View Disclosure  - Contact Me
    Val Gebski, NHMRC Clinical Trials Centre  - View Disclosure  - Contact Me
    Peter Gibbs, Royal Melbourne Hospital  - View Disclosure  - Contact Me
    Volker Heinemann, MD, Comprehensive Cancer Center, Ludwig-Maximilian-University of Munich, Germany  - View Disclosure  - Contact Me
    Marc Peeters, Antwerp University Hospital  - View Disclosure  - Contact Me
    Jens Ricke, University Clinic Magdeburg  - View Disclosure  - Contact Me
    Mark van Buskirk, Data Reduction LLC  - View Disclosure  - Contact Me
    Guy van Hazel, University of Western Australia  - View Disclosure  - Contact Me
 
watchlist Created with Sketch. Add SRX (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.